CSIMarket
 
Third Harmonic Bio Inc   (THRD)
Other Ticker:  
 
 
Price: $11.0500 $-0.60 -5.150%
Day's High: $12.14 Week Perf: -2.04 %
Day's Low: $ 10.39 30 Day Perf: 19.33 %
Volume (M): 793 52 Wk High: $ 12.42
Volume (M$): $ 8,763 52 Wk Avg: $7.52
Open: $11.70 52 Wk Low: $4.06



 Market Capitalization (Millions $) 439
 Shares Outstanding (Millions) 40
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 16
 Cash Flow (TTM) (Millions $) -25
 Capital Exp. (TTM) (Millions $) 0

Third Harmonic Bio Inc
Third Harmonic Bio Inc is a biotechnology company that specializes in the development of immunotherapies for cancer treatment. The company focuses on leveraging the power of the immune system to target and destroy cancer cells. Their innovative approach involves the use of proprietary technology to harness the immune system's natural ability to recognize and eliminate cancerous cells. Third Harmonic Bio Inc is committed to advancing the field of cancer immunotherapy and improving patient outcomes.


   Company Address: 1700 Montgomery Street San Francisco 94111 CA
   Company Phone Number: 727-2457   Stock Exchange / Ticker: NASDAQ THRD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Grifols Sa

Revenue have been $0 million at the company in fiscal period closing December 31 2023

For the fiscal period closing December 31 2023 Grifols Sa reached balanced books of $0.00 per share compare to $0.00 a year ago and from $0.00 per share from the previous reporting period. The revenue remained unaltered to $0.00 million from $0.00 million in the corresponding reporting period a year ago and sequentially from $0.00 million.

Biodexa Pharmaceuticals Plc

Observing the fourth quarter of 2023 results, the Major Pharmaceutical Preparations company's saw it had very pressing period

For the fourth quarter of 2023 earnings season BDRX reached balanced books of $0.00 per share compare to $0.00 a year ago and from $0.00 per share from the preceding financial reporting period. The revenue faded by -45.494 % to $0.38 million from $0.70 million in the same financial reporting period a year ago and sequentially from $0.00 million.

Addex Therapeutics Ltd

A deficit of $-0.14 per Share at the Addex Therapeutics Ltd in fourth quarter of 2023 earnings season

Although Addex Therapeutics Ltds' revenue increased by 13.394 % from the same reporting period a year prior to $1.61 million in the fourth quarter of 2023 earnings season, the Major Pharmaceutical Preparations company lost money at $-0.14 deficit per share.

Axim Biotechnologies Inc

The Diminishing Returns have widen more at the Axim Biotechnologies Inc in the October to December 31 2023 fiscal time-frame

For the October to December 31 2023 fiscal time-frame AXIM increased a deficit per share of $-0.02 per share compare to $0.00 a year prior and from $0.00 per share from the preceding financial reporting period. The revenue grew strongly by 66.79 % to $0.01 million from $0.01 million in the corresponding financial reporting period a year prior and sequentially revenue surged by 31.625 % from $0.01 million.

Neximmune Inc

The company reported operating loss in the fourth quarter of 2023

While the October to December 31 2023 reporting cycle goes on, many corporations have reported the results. Among them, are many constituents of the Major Pharmaceutical Preparations sector. And today, NEXI reported operating loss of $-5.367787 million, for the fiscal fourth quarter of 2023.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com